Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Stomach Neoplasms 16Biliary Tract Neoplasms 4Pancreatic Neoplasms 3Adenocarcinoma 3Esophageal Neoplasms 2Cholangiocarcinoma 2Recurrence 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic cancer, adult 1Neoplasms 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1NSCLC 1Locally Advanced Gastric or Gastroesophageal Junction Cancer 1Locally Advanced Gastric Cancer 1Klatskin Tumor 1Gastric Cancer Peritoneal Metastases 1Gastric Adenocarcinoma 1Gallbladder Neoplasms 1Colorectal Neoplasms 1Chemotherapy Effect 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Bile Duct Neoplasms 1

Interventions

Radiotherapy 4osimertinib 3aflutinib 3Radiosurgery 3Pemetrexed 3Drug Therapy 3Carboplatin 3toripalimab 2pembrolizumab 2Docetaxel 2tislelizumab 1sugemalimab 1lenvatinib 1cemiplimab 1brigatinib 1Vinorelbine 1Tyrosine Kinase Inhibitors 1Surgical Procedures, Operative 1S 1 (combination) 1Platinum Compounds 1Platinum 1Pharmaceutical Preparations 1Paclitaxel 1Neoadjuvant Therapy 1JDQ443 1Immune Checkpoint Inhibitors 1HM781-36B 1Gemcitabine 1Diphenhydramine 1Cryotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NSCLC × S 1 (combination) × 1 year × Clear all
NCT05773092 2025-09-03

A Phase 2 Study of Osimertinib and S-1 in Treatment Resistant EGFR Mutant NSCLC

National Cancer Centre, Singapore

Phase 2 Active not recruiting
30 enrolled
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡